VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2015 | Efficacy and safety of CD19-targeted CAR T-cells for relapsed/refractory ALL

At the 20th Congress of the European Hematology Association (EHA), Dieter Hoelzer, MD, PhD, of Goethe University Hospital, Frankfurt, Germany, discusses the outcomes of clinical trials evaluating treatment using chimeric antigen receptor (CAR)-modified T-cells with specificity for CD19 for adult and pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter